Patents by Inventor Robert E. Neal

Robert E. Neal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12599432
    Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: April 14, 2026
    Assignee: Galvanize Therapeutics, Inc.
    Inventors: Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Jonathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo, Robert E. Neal, William Sanford Krimsky, Quim Castellvi
  • Patent number: 12232792
    Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: February 25, 2025
    Assignees: Virginia Tech Intellectual Properties, Inc., AngioDynamics, Inc.
    Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
  • Publication number: 20240390672
    Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
    Type: Application
    Filed: January 18, 2024
    Publication date: November 28, 2024
    Applicant: Galvanize Therapeutics, Inc.
    Inventors: Robert E. Neal, William S. Krimsky, Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Quim Castellvi, Johnathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo, Chiara Pastori, Ebtesam He Nafie, Mukta S. Wagh
  • Publication number: 20240350187
    Abstract: Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and/or other pulmonary diseases or disorders.
    Type: Application
    Filed: April 24, 2024
    Publication date: October 24, 2024
    Applicant: Galvanize Therapeutics, Inc.
    Inventors: Jonathan Reuben Waldstreicher, William Sanford Krimsky, Denise M. Zarins, Robert J. Beetel, Paul Brian Friedrichs, Kevin James Taylor, Roman Turovskiy, Robert E. Neal
  • Patent number: 11974800
    Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: May 7, 2024
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Michael B. Sano, Rafael V. Davalos, John L Robertson, Paulo A. Garcia, Robert E. Neal
  • Publication number: 20240074804
    Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 7, 2024
    Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
  • Publication number: 20220104875
    Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
    Type: Application
    Filed: October 15, 2021
    Publication date: April 7, 2022
    Applicant: Galary, Inc.
    Inventors: SETH S. GLEIMAN, NICHOLAS S. MERCER, TIMOTHY J. O'BRIEN, JONATHAN R. WALDSTREICHER, KEVIN J. TAYLOR, LUIS L. MANGUAL ARBELO, ROBERT E. NEAL, WILLIAM SANFORD KRIMSKY, QUIM CASTELLVI
  • Publication number: 20200323576
    Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.
    Type: Application
    Filed: May 4, 2020
    Publication date: October 15, 2020
    Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
  • Publication number: 20200197073
    Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.
    Type: Application
    Filed: January 20, 2020
    Publication date: June 25, 2020
    Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
  • Patent number: 10537379
    Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: January 21, 2020
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
  • Publication number: 20180125565
    Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.
    Type: Application
    Filed: December 15, 2017
    Publication date: May 10, 2018
    Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
  • Patent number: 8992517
    Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: March 31, 2015
    Assignee: Virginia Tech Intellectual Properties Inc.
    Inventors: Rafael V. Davalos, Paulo A. Garcia, John H. Rossmeisl, John L. Robertson, Robert E. Neal
  • Publication number: 20130253415
    Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.
    Type: Application
    Filed: November 23, 2011
    Publication date: September 26, 2013
    Applicant: Virginia Tech Intellectual Properties, Inc.
    Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
  • Publication number: 20100030211
    Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.
    Type: Application
    Filed: June 24, 2009
    Publication date: February 4, 2010
    Inventors: Rafael Davalos, Paulo A. Garcia, John H. Rossmeisl, John L. Robertson, Robert E. Neal